Enzychem Lifesciences

183490 · KOSDAQ

Public Market Listing

183490KOSDAQ

KOSDAQ primary exchange listing

Live quotes, historical charts, and market capitalization for Enzychem Lifesciences are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
NF-kB / CCL26 pathwaySmall molecule
Atopic Dermatitis

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
MosedipimodPhase 2Atopic Dermatitis
Est. primary completion 2027-10 · NCT06487000 · CT.gov ↗
What to watch
December 2027 (1)
MosedipimodPhase 2Covid19 Pneumonia
Est. primary completion 2027-12-30 · NCT04569227 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.